tafluprost (Rx)

Brand and Other Names:Zioptan
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic solution

  • 0.0015% (0.015mg/mL)
more...

Elevated Intraocular Pressure

Indicated for reducing elevated IOP in patients with open-angle glaucoma or ocular hypertension

Instill 1 drop in affected eye(s) once daily in the evening

Administration

Instill into conjunctival sac of affected eye(s)

Do not exceed once daily dosing regimen; more frequent administration of prostaglandin analogs may lessen the IOP lowering effect

Reduction of intraocular pressure starts approximately 2 - 4 hours after first administration with maximum effect reached after 12 hr

If other topical ophthalmics are prescribed, each should be administered 5 minutes apart

Preservative free product; use immediately after opening one unit-dose for administration; sterility cannot be maintained after opening

Not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use

Next:

Interactions

Interaction Checker

and tafluprost

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Conjunctival hyperemia (4-20%)

            1-10%

            Ocular stinging (7%)

            Ocular pruritus/allergic conjunctivitis (5%)

            Cataract (3%)

            Growth of eyelashes (2%)

            Blurred vision (2%)

            Postmarketing Reports

            Periorbital and lid changes including deepening of the eyelid sulcus observed with prostaglandin analogs

            Eye disorders: Iritis/uveitis

            Respiratory disorders: Exacerbation of asthma, dyspnea

            Previous
            Next:

            Warnings

            Contraindications

            None

            Cautions

            Causes changes to pigmented tissues; most frequently reported changes have been of the iris, eyelid, and eyelashes; pigmentation changes of the iris is likely permanent Increases length, color, thickness, and number of eyelashes

            Caution with active intraocular inflammation (may exacerbate condition)

            Macular edema reported; caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C; teratogenic when administered IV in rats and rabbits

            Lactation: Unknown whether distributed in breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Prostaglandin analog; exact mechanism by which it reduces IOP is unknown, but it is thought to increase uveoscleral outflow

            Absorption

            Bioavailability: Absorbed through the cornea

            Onset: 2-4 hr; peak effect at 12 hr

            Peak Plasma Time: 10 minutes

            Peak Plasma Concentration: 26 pg/mL

            AUC: 394-432 pg•min/mL

            Metabolism

            Tafluprost is an ester prodrug that is metabolized by hydrolysis to the biologically active acid metabolite (tafluprost acid)

            Elimination

            Mean plasma concentration of tafluprost acid were below the limit of quantification (ie, 10 pg/mL) at 30 minutes following topical ocular administration

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous